| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| VitB1/Thiamine Vitamin B1 (thiamine) is an essential water-soluble vitamin required for carbohydrate metabolism and mitochondrial energy production. Its active form, thiamine pyrophosphate (TPP), is a cofactor for key enzymes including pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (α-KGDH), and transketolase. In Alzheimer’s disease (AD), thiamine deficiency and reduced activity of thiamine-dependent enzymes have been repeatedly observed in brain tissue. Impaired glucose metabolism is a hallmark of AD (“type 3 diabetes” hypothesis), and thiamine-dependent enzyme dysfunction contributes to mitochondrial impairment, oxidative stress, and neuronal vulnerability. Experimental studies suggest thiamine and lipophilic derivatives (e.g., benfotiamine) may improve glucose metabolism, reduce advanced glycation end products (AGEs), attenuate oxidative stress, and modulate neuroinflammation. Clinical data are mixed but suggest possible benefit in selected populations or with higher-bioavailability derivatives. Benfotiamine is a fat-soluble derivative of vitamin B1 (thiamine) that’s used to support nerve health, glucose metabolism, and potentially brain function, including in conditions like Alzheimer’s disease (AD) and diabetic neuropathy. -fat-soluble form, so may absorb better when taken with a meal containing fat. Condition / Purpose Typical Dose Range Notes Alzheimer’s Disease (AD) 300–600 mg/day Used in clinical trials (e.g., 300 mg twice daily) Diabetic Neuropathy 300–600 mg/day Most common clinical application General Cognitive Support 150–300 mg/day Lower end for maintenance High-dose experimental use 900–1,200 mg/day Occasionally used under supervision in research Alzheimer’s Disease Table: Vitamin B1 (Thiamine)
TSF: P = minimal immediate effect; R = metabolic enzyme activation; G = long-term neuroprotective adaptation. Thiamine vs Benfotiamine Comparison Table
|
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 1888- | VitB1/Thiamine, | DCA, | High Dose Vitamin B1 Reduces Proliferation in Cancer Cell Lines Analogous to Dichloroacetate |
| - | in-vitro, | PC, | SK-N-BE | - | NA, | PC, | PANC1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:264 Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid